Superficial Ewing Sarcoma and Neurocristic FET::ETS Tumors: Defining a Diagnostic Gray Zone
In brief
Two ambiguous superficial tumors metastasized despite an SNT-like methylation profile
In this 14-tumor series, DNA methylation grouped all SOX10-expressing tumors with superficial neurocristic tumors, including difficult-to-classify cases. Yet two ambiguous tumors had high-grade features and distant metastases, and one patient died of disease. The authors recommend treating high-grade or ambiguous lesions as Ewing sarcoma for clinical purposes until these rare tumors are better understood.
- Journal
- Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (Q1)
- Published
- 9 November 2026
- Study design
- Unclassified
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Faizan Malik, Karen J Fritchie, Baptiste Ameline, Michael Michal, Zsombor Melegh, Catherine K Gestrich, et al.
- PMID
- 43003232
- DOI
- 10.1016/j.modpat.2026.101113
Why clinicians should know about it
- Picked for Pathology and Forensic Medicine (top studies of the week, 15 November 2026): Diagnostic classification, immunohistochemistry, and methylation profiling
Abstract
Superficial small round cell tumors harboring FET::ETS fusions and expressing S100 and/or SOX10 present a diagnostic challenge, as they raise consideration of both Ewing sarcoma and superficial neurocristic tumor (SNT), with distinct clinical implications. We performed clinicopathologic, immunohistochemical, and DNA methylation analysis on 14 superficial small round cell tumors with S100, variable SOX10 expression, and FET::ETS fusions (n=12) or EWSR1 rearrangements (n=2). The cohort included 9 females and 5 males (age 10-70 years). Tumors were classified as SNT (n=2) based on the presence of morphologic features reported in the initial descriptions: (1) superficial location, (2) nests or cords of bland round to ovoid cells, (3) lack of necrosis, and (4) diffuse co-expression of S100 and SOX10. Cases of Ewing sarcoma (n=8) were composed of nests or sheets of primitive round cells with malignant cytology regardless of S100/SOX10 status, while cases with some but not all features of SNT were labeled "Difficult to classify" (n=4). Clustering by DNA methylome was concordant with histologic classification in 9 of 10 confidently classified tumors and consistently classified all SOX10-expressing tumors as SNT regardless of morphology, including the "Difficult to classify" cases. Differential methylation analysis demonstrated hypomethylation of neural crest-related genes in SNT. Copy number variation was significantly higher in the Ewing sarcoma methylation cluster, with recurrent chromosome 8 gains, whereas tumors in the SNT cluster were largely copy number neutral. Despite clustering with SNT by DNA methylation profiling, two of the "Difficult to classify" cases showed at least focal high-grade cytology and had distant metastases, including one dying of disease. Pooled survival analysis of published and current cases demonstrated superior outcome of SNT when compared to all Ewing sarcomas, but no significant differences in overall survival comparing SNT to superficial Ewing sarcoma. Our findings support a cautious diagnostic approach, reserving the diagnosis of SNT for tumors with classic morphologic and immunophenotypic features, while regarding cytologically high-grade or ambiguous lesions as representing Ewing sarcoma for clinical purposes, until the precise nosology of these exceptionally rare tumors is better understood.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.